Company profile · Sponsor
Bioprojet
Bioprojet Pharma
- Pipeline
- 11
- Drugs
- 0
- Patents
- 0
Quick answer
Bioprojet (ED609B2) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..
Company facts
Pipeline (11)
Search pipeline →-
Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets
Bioprojet
Narcolepsy
1 trial -
Matches test product
Bioprojet
Essential tremor
1 trial -
Matches test product
Bioprojet
Primary premature ejaculation
1 trial -
Matching film-coated placebo tablet
Bioprojet
Obsessive compulsive disorder
1 trial -
Matching orodispersible placebo tablet
Bioprojet
Eosinophilic esophagitis
1 trial -
A first-in-human, randomized, double-blind, placebo-controlled, three-part study assessing the safety, tolerability, pharmacokinetics and pharmacodynamics of BP1.15205 after single and repeated oral ascending doses, including the BP1.15205 effect on cardiac repolarization, as well as an exploratory assessment of the food effect on the pharmacokinetics of BP1.15205 in healthy participants
Bioprojet
Narcolepsy
1 trial -
Exploratory study to assess the pharmacokinetic interaction of doxepin with adrenaline after a concomitant co-administration using the Anapen® device and to compare the adrenaline comparative bioavailability with Anapen®500 commercial form in healthy normal weight male subjects
Bioprojet
Anaphylaxis
1 trial -
Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects.
Bioprojet
narcolepsy with cataplexy, Narcolepsy
1 trial -
Open label, single-center, cross-over randomized, relative bioavailability study comparing a new pitolisant hydrochloride tablet formulation at 4 different strengths versus the marketed pitolisant (Wakix®) tablet formulation after single oral administrations in healthy subjects
Bioprojet
Narcolepsy, Narcolepsy with cataplexy
1 trial -
Open label, single-center, two-part pharmacokinetic study: Part I: Relative bioavailability study to compare the pharmacokinetics of BP1.4979 after administration of single oral doses of BP1.4979 as sustained release formulation and actual immediate release formulation, under fasting and fed conditions, in healthy subjects. Part II: Pharmacokinetics of BP1.4979 after a 14-day dosing period with b.i.d. administration of BP1.4979 as sustained release formulation in healthy subjects.
Bioprojet
Binge eating disorder
1 trial -
Randomized, double-blind, placebo-controlled, two-part study assessing the safety, tolerability and pharmacokinetics of BP1.7881 administered as higher doses, after single ascending doses (Part I) and multiple ascending doses (Part II), including the assessment of BP1.7881 on cardiac repolarization, in healthy subjects.
Bioprojet
Eosinophilic esophagitis
1 trial
Frequently asked questions
What is Bioprojet?
Bioprojet (ED609B2) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 11 pipeline programs, 0 drugs, and 0 patents to this profile..
What pipeline programs does Bioprojet sponsor?
We track 11 ClinicalTrials.gov-linked programs for Bioprojet, including Matches test film-coated tablets, Wakix 4.5 mg film-coated tablets, Wakix 18 mg film-coated tablets and 10 more. Open each program for phase, modality, NCT IDs, and indication details.
Where does Bioprojet company data come from?
Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.